Investment analysts at Barclays assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report issued on Wednesday. The firm set an “equal weight” rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. J P Morgan Chase & Co upped their price objective on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $9.00.

BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $5.01 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.53 and a debt-to-equity ratio of 0.21. BioCryst Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). The firm had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.16) EPS. equities analysts anticipate that BioCryst Pharmaceuticals will post -0.71 EPS for the current fiscal year.

In other news, CMO William P. Sheridan sold 64,310 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $4.72, for a total transaction of $303,543.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.60% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of BCRX. Bank of America Corp DE grew its stake in shares of BioCryst Pharmaceuticals by 43.3% during the 1st quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 7,568 shares during the period. Credit Suisse AG lifted its holdings in BioCryst Pharmaceuticals by 71.5% during the 1st quarter. Credit Suisse AG now owns 110,837 shares of the biotechnology company’s stock worth $931,000 after purchasing an additional 46,204 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of BioCryst Pharmaceuticals by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 1,500 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the 2nd quarter. Rhumbline Advisers now owns 94,303 shares of the biotechnology company’s stock valued at $524,000 after acquiring an additional 6,835 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at about $311,000. Institutional investors own 84.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BioCryst Pharmaceuticals (BCRX) Receives New Coverage from Analysts at Barclays” was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/biocryst-pharmaceuticals-bcrx-receives-new-coverage-from-analysts-at-barclays/1774324.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.